Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
9.61
-0.21 (-2.14%)
At close: Aug 14, 2026, 4:00 PM EDT
9.62
+0.01 (0.10%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Satellos Bioscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
200.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Invivyd | 55.87M |
| Precision BioSciences | 45.06M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 34.46M |
| Tonix Pharmaceuticals Holding | 29.10M |
| Keros Therapeutics | 15.01M |
MSLE News
- 2 days ago - Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - GlobeNewsWire
- 2 days ago - Satellos Bioscience Registration statement: Q2 2026 - Filings
- 2 days ago - Satellos Bioscience Registration statement: Q2 2026 - Filings
- 2 days ago - Satellos Bioscience Earnings release: Q2 2026 - Filings
- 4 days ago - Satellos files $300M mixed securities shelf - TheFly
- 5 days ago - Satellos Bioscience Registration statement: Registration filing - Filings
- 5 weeks ago - Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - MarketBeat
- 5 weeks ago - Satellos price target raised to $18 from $11 at H.C. Wainwright - TheFly